CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

BACKGROUND: Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to evaluate real‐world outcomes with the clinical implementa...

Descripción completa

Detalles Bibliográficos
Autores principales: Beitelshees, Amber L., Thomas, Cameron D., Empey, Philip E., Stouffer, George A., Angiolillo, Dominick J., Franchi, Francesco, Tuteja, Sony, Limdi, Nita A., Lee, James C., Duarte, Julio D., Kreutz, Rolf P., Skaar, Todd C., Coons, James C., Giri, Jay, McDonough, Caitrin W., Rowland, Rachel, Stevenson, James M., Thai, Thuy, Vesely, Mark R., Wellen, Jacob T., Johnson, Julie A., Winterstein, Almut G., Cavallari, Larisa H., Lee, Craig R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245803/
https://www.ncbi.nlm.nih.gov/pubmed/35156424
http://dx.doi.org/10.1161/JAHA.121.024159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245803/
https://www.ncbi.nlm.nih.gov/pubmed/35156424
http://dx.doi.org/10.1161/JAHA.121.024159

Ejemplares similares